The sale of 33,416 shares generated a total value of approximately $1.7 million based on a weighted average execution price of $49.85. The traded shares represent 13% of the equity stake held by the officer before the transaction.
HeartFlow delivered a convincing Q2 with 48% sales growth and gross margins rising to 83%, driving strong market optimism. The company raised full-year revenue guidance to $246–$250 million, though the outlook appears conservative given recent momentum and sequential growth. Shares now trade at 13x sales, supported by accelerating topline growth, expanding plaque-related revenue, and commercial adoption of its non-invasive cardiac solution.
HeartFlow, Inc. (HTFL) Q2 2026 Earnings Call Transcript
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Curtis Ellergodt Rothschild Investment LLC | 222 | $6,012.22 | $12,356.52 | $6,344.3 | 105.52% |
| BG Bart Gancher Intech Investment Management LLC | 16,384 | $480,706.56 | $912,274.23 | $431,567.67 | 89.78% |
| GN Gina Nelson Next Century Growth Investors LLC | 671,404 | $16.43M | $37.36M | $20.93M | 127.43% |
| KM Kristin Mariani Janus Henderson Group PLC | 865,560 | $29.13M | $49.34M | $20.2M | 69.34% |
| MM Mike Muhizi SG Americas Securities LLC | 7,420 | $216,056 | $421,530.2 | $205,474.2 | 95.1% |
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MO Matt OBrien Piper Sandler | 2,488.42 | $104,712.78 | $142,263.06 | $37,550.28 | 35.86% |
| Health Care Technology Industry | Healthcare Sector | John Farquhar CEO | NASDAQ (NMS) Exchange | 42238D107 CUSIP |
| US Country | 843 Employees | - Last Dividend | - Last Split | - IPO Date |